Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free ORIC Stock Alerts

Oric Pharmaceuticals (ORIC) Financials

Oric Pharmaceuticals logo
$12.79 -0.09 (-0.70%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$12.80 +0.02 (+0.12%)
As of 09/18/2026 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Oric Pharmaceuticals

Annual Income Statements for Oric Pharmaceuticals

This table shows Oric Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -25 -74 -79 -89 -101 -128 -129
Consolidated Net Income / (Loss)		 -21 -27 -74 -79 -89 -101 -128 -129
Net Income / (Loss) Continuing Operations		 -21 -25 -73 -79 -89 -101 -128 -129
Total Pre-Tax Income 		-21 -27 -74 -79 -89 -101 -128 -129
Total Operating Income		 -22 -29 -74 -79 -92 -111 -143 -143
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 22 29 74 79 92 111 143 143
Selling, General & Admin Expense		 3.35 5.73 13 22 25 26 29 33
Research & Development Expense		 19 23 61 57 67 85 114 110
Total Other Income / (Expense), net		 1.01 1.69 0.48 0.16 2.65 10 15 14
Basic Earnings per Share		 ($12.32) ($14.15) ($3.36) ($2.07) ($2.25) ($1.96) ($1.83) ($1.47)
Weighted Average Basic Shares Outstanding		 1.73M 1.90M 21.94M 37.95M 39.66M 51.45M 69.73M 87.79M
Diluted Earnings per Share		 ($12.32) ($14.15) ($3.36) ($2.07) ($2.25) ($1.96) ($1.83) ($1.47)
Weighted Average Diluted Shares Outstanding		 1.73M 1.90M 21.94M 37.95M 39.66M 51.45M 69.73M 87.79M
Weighted Average Basic & Diluted Shares Outstanding		 1.73M 1.90M 21.94M 37.95M 45.09M 67.38M 71.03M 100.36M

Quarterly Income Statements for Oric Pharmaceuticals

This table shows Oric Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -28 -25 -32 -35 -37 -30 -36 -33 -31 -36 -41
Consolidated Net Income / (Loss)		 -28 -25 -32 -35 -36 -30 -36 -33 -31 -36 -41
Net Income / (Loss) Continuing Operations		 -28 -25 -32 -35 -36 -30 -36 -33 -31 -36 -41
Total Pre-Tax Income 		-28 -25 -32 -35 -36 -30 -36 -33 -31 -36 -41
Total Operating Income		 -31 -29 -36 -38 -40 -33 -39 -37 -35 -40 -45
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 31 29 36 38 40 33 39 37 35 40 45
Selling, General & Admin Expense		 6.95 7.03 7.08 7.12 7.60 8.08 8.52 7.90 8.70 8.18 9.00
Research & Development Expense		 24 22 29 31 32 25 31 29 26 31 36
Total Other Income / (Expense), net		 3.10 3.98 4.05 3.75 3.26 2.70 2.71 4.08 4.05 3.85 3.80
Basic Earnings per Share		 ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42) ($0.47) ($0.33) ($0.25) ($0.34) ($0.38)
Weighted Average Basic Shares Outstanding		 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M 78.13M 98.95M 87.79M 105.47M 108.01M
Diluted Earnings per Share		 ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42) ($0.47) ($0.33) ($0.25) ($0.34) ($0.38)
Weighted Average Diluted Shares Outstanding		 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M 78.13M 98.95M 87.79M 105.47M 108.01M
Weighted Average Basic & Diluted Shares Outstanding		 67.38M 67.42M 70.54M 70.57M 71.03M 71.09M 97.12M 97.39M 100.36M 103.52M 103.65M

Annual Cash Flow Statements for Oric Pharmaceuticals

This table details how cash moves in and out of Oric Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 17 47 -11 148 -159 -43 36 -14
Net Cash From Operating Activities		 -21 -24 -45 -60 -75 -86 -113 -111
Net Cash From Continuing Operating Activities		 -21 -24 -45 -60 -75 -86 -113 -111
Net Income / (Loss) Continuing Operations		 -21 -27 -74 -79 -89 -101 -128 -129
Consolidated Net Income / (Loss)		 -21 -27 -74 -79 -89 -101 -128 -129
Depreciation Expense		 0.90 1.03 0.97 0.90 0.97 1.03 1.11 1.22
Amortization Expense		 0.00 0.00 0.30 1.35 -1.04 -6.17 -8.10 -2.30
Non-Cash Adjustments To Reconcile Net Income		 0.48 1.10 25 13 15 15 20 25
Changes in Operating Assets and Liabilities, net		 -0.71 1.22 2.05 4.07 -0.45 4.90 1.97 -5.46
Net Cash From Investing Activities		 -0.51 -0.77 -216 158 -109 -43 22 -148
Net Cash From Continuing Investing Activities		 -0.51 -0.77 -216 158 -109 -43 22 -148
Purchase of Property, Plant & Equipment		 -0.53 -0.77 -0.67 -0.94 -2.08 -0.85 -1.19 -0.71
Purchase of Investments		 0.00 0.00 -225 -70 -238 -239 -252 -400
Sale and/or Maturity of Investments		 0.00 0.00 10 229 131 197 275 253
Net Cash From Financing Activities		 38 71 251 49 25 86 127 245
Net Cash From Continuing Financing Activities		 38 71 251 49 25 86 127 245
Repurchase of Common Equity		 - - - - - - -0.17 -2.40
Issuance of Common Equity		 0.00 0.00 271 50 26 86 126 246
Other Financing Activities, net		 0.08 0.13 0.44 0.99 0.08 0.06 0.63 1.98

Quarterly Cash Flow Statements for Oric Pharmaceuticals

This table details how cash moves in and out of Oric Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -2.85 33 -6.53 -5.60 15 -10 27 -26 -4.00 11 -19
Net Cash From Operating Activities		 -24 -30 -26 -29 -28 -33 -31 -25 -22 -32 -32
Net Cash From Continuing Operating Activities		 -24 -30 -26 -29 -28 -33 -31 -25 -22 -32 -32
Net Income / (Loss) Continuing Operations		 -28 -25 -32 -35 -36 -30 -36 -33 -31 -36 -41
Consolidated Net Income / (Loss)		 -28 -25 -32 -35 -36 -30 -36 -33 -31 -36 -41
Depreciation Expense		 0.26 0.26 0.27 0.27 0.30 0.30 0.31 0.29 0.32 0.27 0.26
Amortization Expense		 -2.12 -2.23 -2.30 -1.95 -1.63 -0.88 -0.59 -0.59 -0.24 0.16 0.29
Non-Cash Adjustments To Reconcile Net Income		 3.94 4.96 5.00 5.06 5.20 6.55 6.57 5.63 6.28 6.90 7.09
Changes in Operating Assets and Liabilities, net		 1.98 -8.17 3.37 2.39 4.38 -8.49 -0.78 2.14 1.66 -4.00 2.24
Net Cash From Investing Activities		 21 -62 18 23 43 22 -77 -111 17 -18 12
Net Cash From Continuing Investing Activities		 21 -62 18 23 43 22 -77 -111 17 -18 12
Purchase of Property, Plant & Equipment		 -0.06 -0.22 -0.33 -0.42 -0.22 -0.39 -0.06 -0.04 -0.23 -0.00 -0.36
Purchase of Investments		 -29 -114 -49 -54 -35 -65 -124 -166 -45 -78 -48
Sale and/or Maturity of Investments		 50 53 68 78 78 88 48 55 63 60 60
Net Cash From Financing Activities		 0.45 125 0.82 0.13 0.58 0.01 134 109 1.50 61 0.83
Net Cash From Continuing Financing Activities		 0.45 125 0.82 0.13 0.58 0.01 134 109 2.26 61 0.83
Issuance of Common Equity		 0.43 125 0.52 - 0.56 0.00 135 110 1.31 61 0.68
Other Financing Activities, net		 0.03 0.20 0.29 0.13 0.01 0.01 0.28 0.75 0.94 1.25 0.15

Annual Balance Sheets for Oric Pharmaceuticals

This table presents Oric Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 94 299 299 247 252 274 409
Total Current Assets		 90 297 241 210 213 262 288
Cash & Equivalents		 89 78 226 67 23 59 46
Short-Term Investments		 0.00 215 11 139 185 197 236
Prepaid Expenses		 0.84 3.10 3.54 4.19 4.41 6.29 6.98
Plant, Property, & Equipment, net		 2.24 1.98 2.41 3.25 2.86 2.92 2.42
Total Noncurrent Assets		 1.85 0.32 56 33 37 8.97 118
Long-Term Investments		 - 0.00 43 22 27 0.00 111
Other Noncurrent Operating Assets		 1.85 0.32 12 12 9.70 8.97 7.25
Total Liabilities & Shareholders' Equity		 94 299 299 247 252 274 409
Total Liabilities		 6.12 9.22 26 25 28 31 25
Total Current Liabilities		 5.35 9.00 15 15 20 25 20
Accounts Payable		 0.15 0.76 1.89 1.32 0.94 1.55 3.82
Accrued Expenses		 5.20 8.25 13 14 20 23 17
Total Noncurrent Liabilities		 0.77 0.22 11 9.44 7.46 6.17 4.11
Other Noncurrent Operating Liabilities		 - 0.22 11 9.44 7.46 6.17 4.11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -90 290 273 222 224 243 384
Total Preferred & Common Equity		 -90 290 273 222 224 243 384
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -90 290 273 222 224 243 384
Common Stock		 2.61 456 518 558 659 806 1,076
Retained Earnings		 -93 -166 -245 -334 -435 -563 -692
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.03 -0.10 -1.29 0.26 0.38 0.79

Quarterly Balance Sheets for Oric Pharmaceuticals

This table presents Oric Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 227 292 274 351 329 302 243 347 431 437 405
Total Current Assets		 193 268 232 324 295 279 211 291 296 290 274
Cash & Equivalents		 59 104 26 56 50 44 49 76 50 56 37
Short-Term Investments		 131 160 201 260 237 228 154 207 237 226 227
Prepaid Expenses		 3.54 4.20 4.94 7.31 8.19 7.06 7.71 8.61 8.45 8.30 8.93
Plant, Property, & Equipment, net		 3.11 3.25 3.06 2.80 2.88 3.09 3.02 2.76 2.56 2.15 2.24
Total Noncurrent Assets		 30 20 39 24 31 20 28 53 133 144 129
Long-Term Investments		 19 9.58 29 15 22 10.00 20 45 126 138 123
Other Noncurrent Operating Assets		 11 11 10 9.21 9.30 9.55 8.37 7.76 7.13 6.60 5.95
Total Liabilities & Shareholders' Equity		 227 292 274 351 329 302 243 347 431 437 405
Total Liabilities		 24 23 27 22 27 28 23 23 24 21 23
Total Current Liabilities		 15 15 19 15 20 21 18 18 20 18 21
Accounts Payable		 1.93 3.19 3.74 2.99 2.31 4.25 5.16 3.13 2.90 2.90 3.87
Accrued Expenses		 13 11 15 12 17 17 12 15 17 15 17
Total Noncurrent Liabilities		 8.97 8.48 7.98 6.93 6.97 6.83 5.50 4.81 4.09 3.43 2.67
Other Noncurrent Operating Liabilities		 8.97 8.48 7.98 6.93 6.97 6.83 5.50 4.81 4.09 3.43 2.67
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 203 269 247 329 302 274 220 324 407 416 381
Total Preferred & Common Equity		 203 269 247 329 302 274 220 324 407 416 381
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 203 269 247 329 302 274 220 324 407 416 381
Common Stock		 561 650 654 789 795 800 812 953 1,068 1,144 1,152
Retained Earnings		 -358 -381 -407 -460 -492 -526 -593 -629 -662 -728 -770
Accumulated Other Comprehensive Income / (Loss)		 -0.50 -0.57 -0.37 -0.16 -0.26 0.72 0.21 0.19 0.62 -0.29 -1.02

Annual Metrics And Ratios for Oric Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oric Pharmaceuticals' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -28.34% -166.92% -5.32% -19.88% -26.21% -29.31% 3.87%
EBIT Growth		 0.00% -27.74% -161.70% -6.55% -16.37% -20.72% -28.99% -0.08%
NOPAT Growth		 0.00% -27.71% -159.67% -6.32% -16.35% -20.72% -28.99% -0.08%
Net Income Growth		 0.00% -25.84% -174.16% -6.80% -13.22% -12.99% -26.96% -1.27%
EPS Growth		 0.00% -14.85% 76.25% 38.39% -8.70% 12.89% 6.63% 19.67%
Operating Cash Flow Growth		 0.00% -13.78% -92.36% -31.53% -26.20% -14.03% -31.48% 1.50%
Free Cash Flow Firm Growth		 0.00% 0.00% -162.00% -4.77% -27.32% -10.21% -35.43% -7.04%
Invested Capital Growth		 0.00% 0.00% -222.70% -93.23% 20.53% -86.50% -17.23% 38.56%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -36.27% 6.55% -0.07% -10.27% -5.35% 4.27%
EBIT Q/Q Growth		 0.00% 0.00% -36.00% 6.51% 0.74% -9.17% -6.04% 3.39%
NOPAT Q/Q Growth		 0.00% 0.00% -35.69% 6.49% 0.74% -9.17% -6.04% 3.39%
Net Income Q/Q Growth		 0.00% 0.00% -37.00% 6.52% 2.11% -8.03% -6.65% 4.29%
EPS Q/Q Growth		 0.00% 0.00% 66.70% -315.63% 2.60% 1.51% -1.67% 15.52%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -30.87% 2.52% 1.26% -11.65% -3.48% 4.78%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 8.33% 1.13% -10.75% -3.63% 0.76%
Invested Capital Q/Q Growth		 0.00% 0.00% -71.10% -49.61% -86.41% -25.17% -53.33% -28.70%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.50% 95.06% 99.59% 99.82% 97.12% 90.90% 89.47% 90.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -30.56% -39.02% -27.98% -35.99% -45.11% -54.73% -41.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 31.29% -20.63% -27.98% -35.99% -45.11% -54.73% -41.27%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 29.84% -25.43% -28.84% -40.08% -44.94% -52.59% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -20 -52 -55 -64 -78 -100 -100
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -15.44% -11.38% -8.19% -9.79% -9.99% -11.33% -9.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -34.61% -41.14% -26.04%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -28 -74 -79 -92 -111 -143 -143
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -27 -73 -77 -92 -116 -150 -144
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.60 2.12 1.05 2.24 2.34 2.07
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.60 2.12 1.05 2.24 2.34 2.07
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.01 -1.01 -1.02 -1.03 -1.04 -1.05 -1.03
Leverage Ratio		 0.00 1.07 1.04 1.06 1.10 1.12 1.13 1.09
Compound Leverage Factor		 0.00 1.02 1.04 1.06 1.07 1.02 1.01 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 202.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -102.40% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 10.48 67.48 12.42 3.46 7.83 7.46 16.75
Noncontrolling Interest Sharing Ratio		 0.00% 202.40% 47.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 16.81 32.96 15.88 13.68 10.39 10.56 14.13
Quick Ratio		 0.00 16.65 32.62 15.64 13.40 10.18 10.30 13.79
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -49 -52 -66 -72 -98 -105
Operating Cash Flow to CapEx		 -4,071.46% -3,064.19% -9,550.21% -6,340.89% -3,616.12% -10,092.82% -9,483.33% -15,585.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -1.19 -3.82 -7.39 -5.87 -11 -13 -7.89
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -1.19 -2.64 -3.57 1.52 -5.08 -1.89 4.95
Enterprise Value (EV)		 0.00 209 750 299 4.88 267 314 404
Market Capitalization		 120 120 1,044 579 233 502 569 797
Book Value per Share		 $0.00 ($47.43) $9.40 $6.93 $5.62 $4.11 $3.45 $3.95
Tangible Book Value per Share		 $0.00 ($47.43) $9.40 $6.93 $5.62 $4.11 $3.45 $3.95
Total Capital		 0.00 88 290 273 222 224 243 384
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -89 -294 -280 -228 -235 -256 -392
Capital Expenditures (CapEx)		 0.51 0.77 0.47 0.94 2.08 0.85 1.19 0.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.51 -5.91 -12 -11 -16 -19 -13
Debt-free Net Working Capital (DFNWC)		 0.00 85 288 225 195 192 237 268
Net Working Capital (NWC)		 0.00 85 288 225 195 192 237 268
Net Nonoperating Expense (NNE)		 5.70 6.88 22 24 25 23 28 29
Net Nonoperating Obligations (NNO)		 0.00 -89 -294 -280 -228 -235 -256 -392
Total Depreciation and Amortization (D&A)		 0.90 1.03 1.27 2.25 -0.08 -5.14 -7.00 -1.08
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.36) ($2.07) ($2.25) ($1.96) ($1.83) ($1.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 36.70M 39.43M 39.66M 51.45M 69.73M 87.79M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.36) ($2.07) ($2.25) ($1.96) ($1.83) ($1.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 36.70M 39.43M 39.66M 51.45M 69.73M 87.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($3.36) ($2.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 21.94M 37.95M 45.09M 67.38M 71.03M 100.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -20 -52 -55 -64 -78 -100 -100
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.85%

Quarterly Metrics And Ratios for Oric Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oric Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 100,358,242.00 103,517,562.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 100,358,242.00 103,517,562.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.36 -0.40
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -48.00% -17.77% -46.33% -31.79% -22.87% -7.57% -3.43% 7.56% 15.72% -17.69% -13.71%
EBIT Growth		 -42.09% -12.90% -44.11% -33.60% -25.91% -12.86% -8.46% 4.30% 12.68% -21.09% -15.95%
NOPAT Growth		 -42.09% -12.90% -44.11% -33.60% -25.91% -12.86% -8.46% 4.30% 12.68% -21.09% -15.95%
Net Income Growth		 -35.89% -4.45% -39.31% -35.67% -28.16% -20.03% -13.74% 5.73% 15.98% -19.14% -14.13%
EPS Growth		 5.77% 30.19% 10.00% -11.36% -6.12% -13.51% -4.44% 32.65% 51.92% 19.05% 19.15%
Operating Cash Flow Growth		 -58.33% -46.34% -21.19% -46.59% -15.59% -7.78% -20.36% 12.80% 19.86% 0.29% -2.47%
Free Cash Flow Firm Growth		 0.47% -57.61% -77.55% -87.86% -52.55% 8.00% -23.85% -2.63% -12.88% -27.17% 2.04%
Invested Capital Growth		 -86.50% 53.85% -24.26% 4.30% -17.23% -42.34% 39.11% 26.80% 38.56% -3.23% -68.83%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.69% 7.01% -22.89% -5.13% -2.27% 18.59% -18.16% 6.04% 6.76% -13.68% -14.17%
EBIT Q/Q Growth		 -9.57% 7.76% -24.24% -6.39% -3.27% 17.32% -19.40% 6.13% 5.78% -14.67% -14.33%
NOPAT Q/Q Growth		 -9.57% 7.76% -24.24% -6.39% -3.27% 17.32% -19.40% 6.13% 5.78% -14.67% -14.33%
Net Income Q/Q Growth		 -11.19% 11.72% -27.80% -8.14% -5.04% 17.31% -21.10% 10.36% 6.39% -17.25% -16.01%
EPS Q/Q Growth		 -11.36% 24.49% -21.62% -8.89% -6.12% 19.23% -11.90% 29.79% 24.24% -36.00% -11.76%
Operating Cash Flow Q/Q Growth		 -23.54% -24.38% 15.11% -12.38% 2.58% -15.97% 5.20% 18.58% 10.47% -44.28% 2.57%
Free Cash Flow Firm Q/Q Growth		 -16.87% -39.43% -1.79% -13.26% 5.10% 15.91% -37.03% 6.15% -4.38% 5.26% -5.56%
Invested Capital Q/Q Growth		 -25.17% 74.19% -116.91% -36.55% -53.33% 68.66% 7.21% -64.14% -28.70% 47.34% -51.76%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 90.14% 86.27% 88.74% 90.21% 91.75% 91.76% 93.07% 88.86% 88.29% 90.28% 91.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -45.11% -38.30% -38.79% -45.98% -54.73% -48.45% -43.82% -39.73% -41.27% -42.57% -39.80%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -45.11% -38.30% -38.79% -45.98% -54.73% -48.45% -43.82% -39.73% -41.27% -42.57% -39.80%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -30.96% -36.63% -43.75% 0.00% -60.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -22 -20 -25 -27 -28 -23 -27 -26 -24 -28 -32
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.73% -1.75% -2.32% -2.88% -3.51% -2.56% -2.83% -1.99% -1.95% -2.50% -2.74%
Return On Investment Capital (ROIC_SIMPLE)		 -9.82% - - - -11.39% -10.42% -8.44% -6.31% -6.29% -6.67% -8.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -31 -29 -36 -38 -40 -33 -39 -37 -35 -40 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -33 -31 -38 -40 -41 -33 -39 -37 -34 -39 -45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.24 2.82 1.58 2.64 2.34 1.80 2.23 2.86 2.07 3.06 2.94
Price to Tangible Book Value (P/TBV)		 2.24 2.82 1.58 2.64 2.34 1.80 2.23 2.86 2.07 3.06 2.94
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.02 -1.02 -1.03 -1.05 -1.01 -1.02 -1.02 -1.03 -1.01 -1.01
Leverage Ratio		 1.12 1.09 1.09 1.11 1.13 1.08 1.08 1.08 1.09 1.07 1.07
Compound Leverage Factor		 1.01 0.94 0.96 1.00 1.03 0.99 1.00 0.96 0.96 0.97 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.87 24.05 9.34 13.62 8.70 7.38 16.97 27.15 17.63 34.09 26.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.39 21.31 15.08 13.15 10.56 12.00 16.13 14.65 14.13 16.33 13.19
Quick Ratio		 10.18 20.83 14.66 12.82 10.30 11.56 15.65 14.23 13.79 15.86 12.76
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -24 -24 -27 -26 -22 -30 -28 -29 -28 -29
Operating Cash Flow to CapEx		 -42,578.95% -13,846.79% -7,695.20% -6,889.23% -12,810.05% -8,406.46% -48,955.56% -71,748.57% -9,904.41% -1,621,900.00% -8,877.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -11 -2.83 -6.13 -8.37 -13 -4.02 -3.73 -6.13 -7.89 -4.15 -6.30
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -5.08 3.30 -1.20 0.38 -1.89 -1.20 2.40 2.24 4.95 -0.13 -2.57
Enterprise Value (EV)		 267 595 168 441 314 173 394 752 404 852 734
Market Capitalization		 502 926 477 723 569 396 722 1,165 797 1,272 1,121
Book Value per Share		 $4.11 $4.88 $4.49 $3.88 $3.45 $3.09 $4.56 $4.19 $3.95 $4.14 $3.68
Tangible Book Value per Share		 $4.11 $4.88 $4.49 $3.88 $3.45 $3.09 $4.56 $4.19 $3.95 $4.14 $3.68
Total Capital		 224 329 302 274 243 220 324 407 384 416 381
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -235 -331 -309 -282 -256 -224 -328 -413 -392 -420 -388
Capital Expenditures (CapEx)		 0.06 0.22 0.33 0.42 0.22 0.39 0.06 0.04 0.23 0.00 0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -7.91 -11 -14 -19 -9.91 -9.44 -12 -13 -9.47 -12
Debt-free Net Working Capital (DFNWC)		 192 309 275 258 237 194 273 275 268 272 253
Net Working Capital (NWC)		 192 309 275 258 237 194 273 275 268 272 253
Net Nonoperating Expense (NNE)		 6.33 4.72 6.75 7.74 8.61 7.12 9.01 6.92 6.32 8.03 9.78
Net Nonoperating Obligations (NNO)		 -235 -331 -309 -282 -256 -224 -328 -413 -392 -420 -388
Total Depreciation and Amortization (D&A)		 -1.86 -1.97 -2.02 -1.68 -1.33 -0.58 -0.28 -0.30 0.08 0.43 0.56
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42) ($0.47) ($0.33) ($0.25) ($0.34) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M 78.13M 98.95M 87.79M 105.47M 108.01M
Adjusted Diluted Earnings per Share		 ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42) ($0.47) ($0.33) ($0.25) ($0.34) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M 78.13M 98.95M 87.79M 105.47M 108.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.38M 67.42M 70.54M 70.57M 71.03M 71.09M 97.12M 97.39M 100.36M 103.52M 103.65M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -20 -25 -27 -28 -23 -27 -26 -24 -28 -32
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.85% -2.51% -1.95%

Financials Breakdown Chart

Key Financial Trends

Oric Pharmaceuticals remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is therefore driven primarily by research spending, investment income, equity financing and cash runway rather than operating sales.

Positive trends:

  • Substantial liquidity remains available. As of June 30, 2026, Oric reported $37.5 million in cash, $227.3 million in short-term investments and $122.8 million in long-term investments, for approximately $387.4 million in cash and investments combined.
  • The balance sheet carries minimal debt-like liabilities. Total liabilities were $23.4 million compared with $381.3 million of equity. Total current assets of $273.7 million were more than 13 times total current liabilities of $20.8 million, providing considerable short-term financial flexibility.
  • Liquidity has grown over the longer period despite quarterly volatility. Cash and investments totaled approximately $387.4 million in Q2 2026, up from about $220.5 million in Q2 2023 and $250.0 million in Q2 2024. The increase was supported largely by equity financings.
  • Investment income helps offset a portion of operating expenses. Other income was $3.8 million in Q2 2026, broadly consistent with the $2.7 million to $4.1 million range reported in most earlier periods.

Neutral factors and items to monitor:

  • Cash management is heavily dependent on investment activity. In Q2 2026, Oric purchased $47.8 million of investments and received $60.0 million from investment sales or maturities, producing $11.9 million of net investing cash inflow. These transactions primarily reflect portfolio management rather than operating growth.
  • Reported cash runway appears meaningful but is not indefinite. Q2 2026 operating cash outflow was $31.6 million. Comparing this quarterly burn with roughly $387.4 million of cash and investments suggests several years of funding capacity, although clinical development costs, trial expansion and future financing needs could materially change the runway.
  • Research spending is rising alongside the development pipeline. Research and development expense increased from $13.8 million in Q2 2022 to $36.3 million in Q2 2026, while SG&A increased from $6.9 million to $9.0 million. Higher spending could support pipeline advancement, but its investment value depends on clinical and regulatory outcomes.
  • Some historical figures were restated. The supplied Q1 and Q2 2025 income statement and cash flow data are marked as restated, so investors should use caution when comparing earlier periods with the latest reported figures.

Negative trends:

  • Oric continues to report zero revenue. Total revenue and gross profit were reported at zero in each income statement period supplied, leaving the company without an operating revenue stream to fund research and administrative costs.
  • Net losses and operating expenses have generally expanded. Q2 2026 operating expenses reached $45.3 million and net loss was $41.5 million, compared with operating expenses of $20.7 million and a net loss of $20.3 million in Q2 2022. The Q2 2026 loss also increased from $35.8 million in Q1 2026.
  • Operating cash burn remains persistent. Oric has generated negative operating cash flow in every supplied quarter, including $31.6 million in Q2 2026. The company must continue funding operations through its investment portfolio, potential partnerships or additional capital raises.
  • Shareholder dilution has been significant. Weighted-average basic shares rose from 39.5 million in Q2 2022 to 108.0 million in Q2 2026. Large equity issuances, including $125.0 million in Q1 2025, $134.7 million in Q2 2025 and $109.7 million in Q3 2025, helped replenish liquidity but increased the ownership base and diluted existing investors.

Overall, Oric’s strong liquidity and low liabilities provide a financial cushion for continued clinical development. However, the company remains dependent on external capital because losses, research spending and operating cash burn are rising while revenue remains absent. For investors, clinical progress and the company’s ability to convert its cash investment into successful products are more important than near-term profitability metrics.

09/19/26 05:03 PM ETAI Generated. May Contain Errors.

Oric Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oric Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Oric Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$129.47 million in 2025, rising from -$21.36 million in 2018. The previous period was -$127.85 million in 2024. Check out Oric Pharmaceuticals' forecast to explore projected trends and price targets.

Oric Pharmaceuticals' total operating income in 2025 was -$143.00 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $143.00 million

Over the last 7 years, Oric Pharmaceuticals' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Oric Pharmaceuticals' total liabilities were at $24.53 million at the end of 2025, a 20.9% decrease from 2024, and a 300.8% increase since 2019.

In the past 6 years, Oric Pharmaceuticals' cash and equivalents has ranged from $23.38 million in 2023 to $226.01 million in 2021, and is currently $45.67 million as of their latest financial filing in 2025.

Over the last 7 years, Oric Pharmaceuticals' book value per share changed from 0.00 in 2018 to 3.95 in 2025, a change of 394.7%.


Related Companies

Financial statements for NASDAQ:ORIC last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel